DHR 8-K filings, explained
Every material Form 8-K Danaher has filed with the SEC since January 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Briefs on record13since Jan 12, 2026
Latest filingOct 20, 2026earnings
High impact (4-5)6of 13 briefs
TonePositive4Mixed1Neutral8
earnings 5leadership 3financing 3shareholder 1m&a 1
2026
Oct 20, 5:43 PM ET
Danaher reported third-quarter 2026 sales of $6.6 billion, up 8.5% year over year, and net earnings of $1.2 billion, or $1.71 per diluted share, up 34.5%. Adjusted diluted EPS rose 11.5% to $2.11, and the company raised its full-year 2026 adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60. For shareholders, the results and higher guidance point to stronger profit, though core revenue growth excluding respiratory testing was 5.5%, and the company expects respiratory testing to be a headwind in the fourth quarter.
- Third-quarter net earnings were $1.2 billion, or $1.71 per diluted share, up 34.5% year over year.
- Adjusted diluted EPS was $2.11, up 11.5% from $1.89 a year earlier.
- Full-year 2026 adjusted diluted EPS guidance was raised to $8.57-$8.62 from $8.45-$8.60.
- Core revenue excluding respiratory testing rose 5.5%; total core revenue rose 3.0%.
Read the filing on SEC.gov ↗
Oct 13, 8:53 AM ET
Danaher's board increased its size to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg as directors effective October 9, 2026. Director Alan G. Spoon will retire from the board at the 2027 annual meeting, and founders Steven and Mitchell Rales waived 500,000-share RSU grants each for no consideration.
- Board increased to thirteen members; Daniel L. Comas and Robert M. Hershberg appointed effective October 9, 2026
- Comas, a former Danaher CFO, ended his consulting agreement effective September 30, 2026, after earning $393,750 in 2026 and $525,000 in 2025
- Alan G. Spoon will not stand for re-election and retires effective at the 2027 annual meeting; he cited no disagreement with the company
- Steven and Mitchell Rales each waived Founder RSUs covering 500,000 shares granted August 4, 2026, for no consideration
Read the filing on SEC.gov ↗
Aug 3, 4:27 PM ET
Danaher's board appointed Julie Sawyer Montgomery, currently Executive Vice President and head of the Diagnostics platform, as President and Chief Executive Officer effective October 1, 2026, and she joins the board at that time. Rainer Blair steps down as CEO and director and will serve as a senior advisor during the transition. The company said its third-quarter and full-year 2026 guidance is unchanged.
- Sawyer Montgomery's base salary as CEO is $1.5 million, with a target annual cash incentive of 200% of base salary.
- She will receive a special stock option award with a target value of $20 million, vesting 50% on the fourth and 50% on the fifth anniversary of the August 4, 2026 grant date.
- Blair will remain a senior advisor through December 31, 2026, then serve as a consultant until March 31, 2027, and is entitled to severance including 12 months of base salary.
- Danaher said there is no change to its previously communicated third-quarter and full-year 2026 guidance.
Read the filing on SEC.gov ↗
Jul 20, 5:55 PM ET
Danaher reported second-quarter 2026 revenue of $6.3 billion, up 5.5% year-over-year, and GAAP net earnings of $870 million, or $1.23 per diluted share, up 60%. The company raised its full-year 2026 adjusted diluted EPS guidance to $8.45-$8.60 from $8.35-$8.55, which points to higher expected per-share profit for shareholders.
- Q2 2026 adjusted diluted EPS was $1.94, up 8.0% year-over-year, and non-GAAP core revenue rose 3.0%.
- Full-year 2026 adjusted diluted EPS guidance rose to $8.45-$8.60 from $8.35-$8.55.
- Third-quarter 2026 core revenue growth is expected at 2.0% to 3.0%, and full-year core revenue growth at 3.0% to 4.0%.
- Operating cash flow was $1.5 billion and free cash flow was $1.3 billion in the quarter, and the Masimo acquisition closed earlier than anticipated.
Read the filing on SEC.gov ↗
Jun 3, 4:30 PM ET
On June 3, 2026, Danaher and its subsidiary DH Masi Finance Inc. closed a private placement of seven series of Swiss franc senior notes, with fixed interest rates from 1.65% to 2.51%. Danaher fully and unconditionally guarantees the unsecured notes, and the company says the net proceeds will fund general corporate purposes, including acquisitions and share repurchases, which adds long-term fixed-rate debt to its balance sheet.
- Seven series of unsecured senior notes were issued by DH Masi Finance Inc. and closed on June 3, 2026, in an offering exempt from Securities Act registration.
- Maturities range from June 3, 2031 (Series A) to June 3, 2056 (Series G).
- Fixed coupons range from 1.65% to 2.51% per year, paid semi-annually beginning December 3, 2026.
- Danaher guarantees the notes; proceeds are expected to fund working capital, acquisitions and share repurchases.
Read the filing on SEC.gov ↗
May 7, 4:36 PM ET
At its May 5, 2026 annual meeting, Danaher shareholders approved an amended and restated Omnibus Incentive Plan that adds 20 million shares to the plan reserve and extends the plan term to May 5, 2036. Shareholders also elected all eleven director nominees, ratified Ernst & Young LLP as auditor for 2026, and approved named executive officer compensation on an advisory basis.
- Plan approved with 553,836,647 votes for and 41,437,418 against, plus 509,591 abstentions and 36,129,645 broker non-votes
- Plan adds 20 million shares of Common Stock to the share reserve and extends the term to May 5, 2036
- Advisory vote on named executive officer compensation passed with 553,754,519 votes for and 41,555,863 against
- Ernst & Young LLP ratified as independent registered public accounting firm for the year ending December 31, 2026
Read the filing on SEC.gov ↗
Apr 29, 4:14 PM ET
On April 29, 2026, Danaher issued four series of euro-denominated senior notes under an April 22 underwriting agreement, receiving net proceeds of approximately €2.98 billion. Danaher intends to use most of the proceeds to pay part of the cash consideration and costs of its proposed Masimo Corporation acquisition. If that deal is not completed by November 16, 2026, or is terminated, Danaher must redeem the notes at 101% of principal.
- Four series issued: €500 million floating rate notes due 2028, €750 million 3.250% notes due 2030, €750 million 3.625% notes due 2034, and €1.0 billion 4.000% notes due 2038.
- Net proceeds of approximately €2.98 billion, to be used mainly for the Masimo Acquisition cash consideration and related costs, with the possibility of general corporate purposes.
- If the Masimo Acquisition is not consummated by November 16, 2026, or the merger agreement is terminated, Danaher must redeem all notes at 101% of principal plus accrued interest.
Read the filing on SEC.gov ↗
Apr 20, 5:44 PM ET
Danaher reported first-quarter 2026 results, with revenue up 3.5% to $6.0 billion and adjusted diluted EPS up 9.5% to $2.06, while GAAP diluted EPS rose to $1.45 from $1.32. The company raised its full-year 2026 adjusted EPS guidance to $8.35 to $8.55 from $8.35 to $8.50, and said it intends to acquire Masimo Corporation.
- Q1 2026 GAAP net earnings were $1.0 billion, or $1.45 per diluted share, versus $1.32 a year earlier.
- Non-GAAP core revenue rose 0.5% year-over-year, with the company citing a lighter-than-typical Q1 respiratory season at Cepheid.
- Full-year 2026 adjusted diluted EPS guidance is now $8.35 to $8.55, up from $8.35 to $8.50; full-year core revenue growth guidance of 3% to 6% was unchanged.
- Danaher announced its intention to acquire Masimo Corporation, subject to customary closing conditions including regulatory approval.
Read the filing on SEC.gov ↗
Apr 17, 8:28 AM ET
Danaher signed a new $5.0 billion 364-day revolving credit facility with Bank of America as administrative agent, expiring April 15, 2027. The company says it will use the facility for liquidity support for its U.S. dollar commercial paper program and general corporate purposes.
- Facility size is $5.0 billion, entered April 16, 2026, and expires April 15, 2027
- Term SOFR loans carry a margin of 58.5 to 108.5 basis points, depending on Danaher's long-term debt rating
- Danaher must maintain a Consolidated Leverage Ratio of 0.65 to 1.00 or less and pays a 4.0 basis point facility fee on commitments
- Certain changes of control would constitute an event of default
Read the filing on SEC.gov ↗
Feb 17, 8:08 AM ET
Danaher agreed to acquire Masimo, a provider of pulse oximetry and patient monitoring products, for $180 per share in cash under a merger agreement dated February 16, 2026. The total enterprise value is approximately $9.9 billion including assumed debt and net of acquired cash, and the deal is expected to close in the second half of 2026 subject to regulatory clearances and Masimo shareholder approval. For Danaher shareholders, the filing projects Masimo to be accretive to adjusted diluted EPS by $0.15 to $0.20 in the first full year and about $0.70 in the fifth full year.
- Price: $180 per share in cash for all outstanding Masimo common stock
- Total enterprise value of approximately $9.9 billion, including assumed indebtedness, net of acquired cash
- Expected accretion to adjusted diluted EPS of $0.15 to $0.20 in the first full year and about $0.70 in the fifth full year
- Expected close in the second half of 2026; Danaher expects to fund the deal with cash on hand and debt financing
Read the filing on SEC.gov ↗
Feb 10, 4:22 PM ET
Danaher Corporation disclosed that director Jessica L. Mega retired from its Board of Directors effective February 5, 2026, citing commitments tied to her other professional obligations. The filing states her decision was not the result of any disagreement with Danaher on its operations, policies or practices.
- Jessica L. Mega notified the Board on February 5, 2026, of her retirement, effective the same day.
- She cited commitments related to her other professional obligations.
- The filing states there was no disagreement with Danaher on operations, policies or practices.
- The 8-K contains no financial results; its only exhibit is an inline XBRL cover page.
Read the filing on SEC.gov ↗
Jan 27, 5:37 PM ET
Danaher reported fourth quarter and full year 2025 results, with revenue and non-GAAP adjusted diluted EPS both higher than the prior year. GAAP full-year diluted EPS fell to $5.03 from $5.29, reflecting impairment charges, and the company initiated 2026 adjusted diluted EPS guidance of $8.35 to $8.50 and core revenue growth of 3% to 6%.
- Full-year 2025 revenue rose 3.0% to $24.6 billion; non-GAAP core revenue rose 2.0%.
- Full-year 2025 adjusted diluted EPS grew 4.5% to $7.80, while GAAP diluted EPS fell to $5.03 from $5.29.
- Fourth quarter 2025 revenue rose 4.5% to $6.8 billion, and adjusted diluted EPS grew 4.0% to $2.23.
- For 2026, the company expects non-GAAP core revenue growth of 3% to 6% and adjusted diluted EPS of $8.35 to $8.50.
Read the filing on SEC.gov ↗
Jan 12, 9:07 AM ET
Danaher estimated that fourth-quarter 2025 revenue rose in the mid-single digit percent range year over year, with non-GAAP core revenue growth toward the high end of its low-single digit guidance. It also expects full-year 2025 non-GAAP adjusted diluted EPS toward the high end of its $7.70 to $7.80 guidance range, which suggests results came in at or above the company's prior outlook. These figures are preliminary estimates ahead of the January 28, 2026 earnings call.
- Q4 2025 estimated revenue growth: mid-single digit percent range year over year
- Q4 2025 non-GAAP core revenue growth expected toward the high end of low-single digit guidance
- FY 2025 non-GAAP adjusted diluted EPS expected toward the high end of the $7.70 to $7.80 range
- CEO Rainer M. Blair to comment at J.P. Morgan Healthcare Conference on January 13, 2026; earnings call January 28, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Danaher filing is on SEC EDGAR ↗. 8-K briefs of other companies →